Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C07
ORGANIC CHEMISTRY
Load children
C07C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
Load children
62/00
Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
Load children Filter patents View analytics View as hierarchy Open in page
C07C62/18
Saturated compounds containing keto groups
Load children Filter patents View analytics View as hierarchy Open in page
C07C62/24
the keto group being part of a ring
Filter patents View analytics View as hierarchy Open in page

C07C62/24

Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV
20170152253 · 2017-06-01 · ·

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-()-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-()-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-()-ephedrine from the precipitated salt obtained in step (b).

Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV
20170152253 · 2017-06-01 · ·

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-()-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-()-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-()-ephedrine from the precipitated salt obtained in step (b).

Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV
09586893 · 2017-03-07 · ·

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-()-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-()-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-()-ephedrine from the precipitated salt obtained in step (b).

Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV
09586893 · 2017-03-07 · ·

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-()-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-()-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-()-ephedrine from the precipitated salt obtained in step (b).